The stock price of Apellis Pharmaceuticals Inc (NASDAQ: APLS) has surged by 3.24 when compared to previous closing price of 17.31, but the company has seen a -3.98% decline in its stock price over the last five trading sessions. prnewswire.com reported 2025-07-01 that STOCKHOLM, July 1, 2025 /PRNewswire/ — Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty obligations to Apellis by 90% for Aspaveli® (systemic pegcetacoplan) in exchange for $275 million upfront and up to $25 million in additional milestone payments dependent on regulatory approvals in the European Union for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). “We are pleased to continue our ongoing partnership with Apellis and share their strong belief in Aspaveli/EMPAVELI’s potential to deliver significant long-term growth,” said Guido Oelkers, Chief Executive Officer at Sobi.
Is It Worth Investing in Apellis Pharmaceuticals Inc (NASDAQ: APLS) Right Now?
APLS has 36-month beta value of 0.66. Analysts have mixed views on the stock, with 10 analysts rating it as a “buy,” 4 as “overweight,” 9 as “hold,” and 0 as “sell.”
The public float for APLS is 103.36M, and currently, short sellers hold a 24.32% ratio of that float. The average trading volume of APLS on July 02, 2025 was 2.60M shares.
APLS’s Market Performance
APLS’s stock has seen a -3.98% decrease for the week, with a 5.55% rise in the past month and a -18.29% fall in the past quarter. The volatility ratio for the week is 3.88%, and the volatility levels for the past 30 days are at 4.52% for Apellis Pharmaceuticals Inc The simple moving average for the last 20 days is -3.19% for APLS stock, with a simple moving average of -31.02% for the last 200 days.
Analysts’ Opinion of APLS
Many brokerage firms have already submitted their reports for APLS stocks, with Raymond James repeating the rating for APLS by listing it as a “Outperform.” The predicted price for APLS in the upcoming period, according to Raymond James is $52 based on the research report published on May 09, 2025 of the current year 2025.
BofA Securities, on the other hand, stated in their research note that they expect to see APLS reach a price target of $23. The rating they have provided for APLS stocks is “Neutral” according to the report published on May 09th, 2025.
Cantor Fitzgerald gave a rating of “Overweight” to APLS, setting the target price at $44 in the report published on April 29th of the current year.
APLS Trading at -1.42% from the 50-Day Moving Average
After a stumble in the market that brought APLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.92% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APLS starting from Watson David O., who sale 5,000 shares at the price of $18.77 back on Jun 16 ’25. After this action, Watson David O. now owns 133,730 shares of Apellis Pharmaceuticals Inc, valued at $93,850 using the latest closing price.
Stock Fundamentals for APLS
Current profitability levels for the company are sitting at:
- -0.24 for the present operating margin
- 0.83 for the gross margin
The net margin for Apellis Pharmaceuticals Inc stands at -0.29. The total capital return value is set at -0.3. Equity return is now at value -103.82, with -27.29 for asset returns.
Based on Apellis Pharmaceuticals Inc (APLS), the company’s capital structure generated 0.74 points at debt to capital in total, while cash flow to debt ratio is standing at -0.02. The debt to equity ratio resting at 2.86. The interest coverage ratio of the stock is -4.19.
Currently, EBITDA for the company is -154.53 million with net debt to EBITDA at -0.63. When we switch over and look at the enterprise to sales, we see a ratio of 3.04. The receivables turnover for the company is 3.17for trailing twelve months and the total asset turnover is 0.96. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.08.
Conclusion
To put it simply, Apellis Pharmaceuticals Inc (APLS) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
